Here are the trials we have forecasted. There is a link at the bottom to request more details about them, including what outcome we predicted for each, what probability we assigned, and how well we did.
| Symbol | Company | Drug Candidate | Phase | Trial | Indication |
| ABBV | AbbVie | Cariprazine | 3 | Two Trials | Major Depression |
| ACAD | Acadia | Trofinetide | 3 | LAVENDER | Rett Syndrome |
| AGLE | Aeglea | Pegzilarginase | 3 | PEACE | Arginase Deficiency |
| ALBO | Albireo | Bylvay (odevixibat) | 3 | ASSERT | Alagille Syndrome |
| ALLK | Allakos | AK002 | 2/3 | KRYPTOS | Eoesinophilic esophagitis (EoE) |
| ALNY | Alnylam | Patisiran (Onpattro) | 3 | APOLLO-B | ATTR-CM |
| AMTI | AMT | AMT 101 | 2 | FILLMORE | Chronic Pouchitis |
| ANAB | AnaptysBio | Imsidolimab | 2 | GALLOP | Generalized Pustular Psoriasis |
| AVXL | Anavex | Blarcamesine | 2/3 | AVATAR | Rett Syndrome |
| APLS | Apellis | Pegcetacoplan | 3 | DERBY / OAKS |
Dry AMD / Geographic Atrophy |
| APTX | Aptinyx | NYX-2925 | 2 | Phase 2 Trial | Diabetic Peripheral Neuropathy |
| ARNA | Arena | Etrasimod | 3 | ELEVATE | Ulcerative Colitis (UC) |
| ASND | Ascendis | Transcon PTH | 3 | PaTHway | Hypoparathyroidism |
| ATHA | Athira | ATH-1017 | 2 | ACT-AD | Alzheimer’s |
| AYLA | Ayala | AL101 | 2 | TENACITY | TNBC |
| BIB / ESALY | Biogen / Eisai | Lecanemab | 3 | CLARITY-AD | Early Alzheimer’s |
| BLU | Bellus | BLU-5937 | 2B | SOOTHE | Chronic Cough |
| BHVN | Biohaven | Troriluzole | 3 | SARA | Spinocerebellar Ataxia |
| BMY | BMS BMY |
Ricolinostat | 2 | Diabetic Peripheral Neuropathy | |
| CMPS | Compass | Psilocybin | 2B | Phase 2/3 Trial | Treatment-Resistant Depression |
| CFRX | Contrafect | Exebacase (CF-301) | 3 | DISRUPT | MRSA |
| CRTX | Cortexyme | COR388 | 2/3 | GAIN | Alzheimer’s |
| GRTX | Galera | Avasopasem | 3 | ROMAN | Radiation-Induced Severe Oral Mucositis |
| GOSS | Gossamer | GB004 | 2 | Phase 2 Trial | Ulcerative Colitis (UC) |
| GOSS | Gossamer | GB002 (Seralutinib) | 2 | TORREY | Pulmonary Arterial Hypertension (PAH) |
| IDRA | Idera | Tilsotolimod | 3 | ILLUMINATE 301 | Metastatic Melanoma |
| IMGN | Immunogen | Mirvetuximab | 3 | SORAYA | Ovarian cancer |
| IMGN | Immunogen | Mirvetuximab | 3 | MIRASOL | Ovarian cancer |
| KRTX | Karuna | KarXT/Xanomeline-Trospium | 3 | EMERGENT-2 | Schizophrenia |
| KPTI | Karyopharm | Xpovio | 3 | SIENDO | Endometriosis cancer |
| KOD | Kodiak | KSI-301 | 2B/3 | DAZZLE | Wet AMD |
| LXRX | Lexicon | LX9211 | 2 | RELIEF-PHN RELIEF-DPN |
Neuropathic Pain |
| MDGL | Madrigal | Resmetirom (MGL-3196) | 3 | MAESTRO | NASH |
| MREO | Mereo | MPH-966 | 2 | ASTRAEUS | Alpha-1 Antitrypsin Deficiency |
| NVS | Novartis | Secukinumab | 3 | SUNSHINE / SUNRISE |
Hidradenitis Suppurativa |
| OBSV | Obseva | Linzagolix | 3 | EDELWEISS | endometriosis pain |
| OTIC | Otonomy | OTO-313 (Gacyclidine) | 2 | Phase 2 | Unilateral Tinnitus |
| PRQR | ProQR | Sepofarsen | 2/3 | ILLUMINATE | Leber Congenital Amaurosis |
| RETA | Reata | Imbarkyd (Bardoxolone) | 2 | MERLIN | Chronic Kidney Disease |
| RLMD | Relmada | REL-1017 (Esmethadone) | 3 | RELIANCE-I | Major Depression – Adjunctive |
| RIGL | Rigel | Fostamatinib | 3 | FORWARD | Autoimmune Hemolytic Anemia (AIHA) |
| SAGE | Sage | Zuranolone | 3 | WATERFALL | Major Depression |
| SNY | Sanofi | Rilzabrutinib | 3 | PEGASUS | Pemphigus |
| STSA | Satsuma | STS101 (Dihydroergotamine mesylate) |
3 | Phase 3 Summit | Migraine |
| SRRA | Sierra | Momelotinib | 3 | MOMENTUM | Myelofibrosis (MF) |
| SWTX | Springworks | Nirogacestat | 3 | DeFI | Desmoid Tumors/Aggressive Fibromatosis (DT/AF) |
| MITO | Stealth | Elamipretide (Systemic Delivery) | 2 | RECLAIM-2 | Dry AMD / Geographic Atrophy |
| VRTX | Vertex | VX-147 | 2 | Phase 2 Trial | Focal Segmental Glomerulosclerosis |
| VRDN | Viridian | VRDN-001 | 2 | Phase 1/2 POC | Thyroid Eye Disease |
| VTGN | Vistagen | PH-94B | 3 | PALISADE-1 | Social Anxiety Disorder |
| XENE | Xenon | XEN1101 | 2 | X-TOLE | Focal Seizures |
Care to see the details? Let us know.